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Summary
We have previously reported an autosomal recessive
form of congenital muscular dystrophy, characterized by
proximal girdle weakness, generalized muscle hypertro-
phy, rigidity of the spine, and contractures of the tendo
Achilles, in a consanguineous family from the United
Arab Emirates. Early respiratory failure resulting from
severe diaphragmatic involvement was present. Intellect
and the results of brain imaging were normal. Serum
creatine kinase levels were grossly elevated, and muscle-
biopsy samples showed dystrophic changes. The ex-
pression of the laminin-a2 chain of merosin was reduced
on several fibers, but linkage analysis excluded the
LAMA2 locus on chromosome 6q22-23. Here, we report
the results of genomewide linkage analysis of this family,
by use of homozygosity mapping. In all four affected
children, an identical homozygous region was identified
on chromosome 1q42, spanning 6–15 cM between
flanking markers D1S2860 and D1S2800.We have iden-
tified a second German family with two affected children
having similar clinical and histopathological features;
they are consistent with linkage to the same locus. The
cumulative LOD score was 3.57 ( ) at markerv = .00
D1S213. This represents a novel locus for congenital
muscular dystrophy. We suggest calling this disorder
“CMD1B.” The expression of three functional candi-
date genes in the CMD1B critical region was investi-
gated, and no detectable changes in their level of ex-
pression were observed. The secondary reduction in
laminin-a2 chain in these families suggests that the pri-
mary genetic defect resides in a gene coding for a protein
involved in basal lamina assembly.
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Introduction
In the past few years, there has been remarkable pro-
gress in the understanding of the genetic and bio-
chemical basis of the muscular dystrophies. The ma-
jority of these conditions are caused by mutations in
genes that encode sarcolemmal or extracellular-matrix
proteins. A deficiency of the sarcolemmal protein dys-
trophin is the hallmark of Duchenne and Becker mus-
cular dystrophies (MIM 310200) (Koenig et al. 1987),
whereas the sarcoglycans are involved in the limb-
girdle muscular dystrophies (LGMDs) (Campbell
1995). The laminin-a2 chain is deficient in merosin-
deficient congenital muscular dystrophy (CMD)
(Tome´ et al. 1994; Dubowitz 1995). A congenital my-
opathy with some clinical and histopathological sim-
ilarities to CMD (Hayashi et al. 1998) is caused by
mutations in the integrin a7 gene. Bethlem myopathy
(MIM 158810), a condition that can mimic CMD
(Jobsis et al. 1999), is the result of defects in collagen
VI (Jobsis et al. 1996; Pan et al. 1998). It has also
been reported that some patients with LGMD have
partial merosin deficiency (Herrmann et al. 1996;
Mora et al. 1996; Naom et al. 1997; Sewry et al. 1997;
Cohn et al. 1998; Muntoni et al. 1998a). The results
of mutational analysis of the laminin-a2 gene
(LAMA2) on chromosome 6q22-23 demonstrated
that this group of patients represents a milder allelic
variant of merosin-deficient CMD (Allamand et al.
1997; Naom et al. 1998, 2000).
A deficiency of extracellular-matrix proteins can also
be found in other muscular dystrophies. A reduced ex-
pression of the laminin chains of merosin has been re-
ported in Fukuyama muscular dystrophy (FCMD [MIM
253800]), a form of CMD with a severe involvement of
the CNS (Hayashi et al. 1993). Since the defective gene
in FCMD has been mapped to chromosome 9, the re-
duction in merosin expression represents a secondary
phenomenon and raises the possibility of the basal lam-
ina playing a major role in the disease. The recent ob-
servation that the FCMD gene product is secreted ex-
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Figure 1 Pedigrees of families 1 (A) and 2 (B), showing the haplotypes for chromosome 1q42 markers. The disease haplotype is denoted
by the gray-shaded bars. The diagonally hatched section of a bar denotes an allele that could not be unequivocally assigned. The CMD1B
critical region is defined, in family 1, by recombination events in patients II.2 and II.4.
tracellularly substantiates this prediction (Kobayashi et
al. 1998). A reduction in the expression of the laminin-
a2 chain of merosin has also been reported in muscle-
eye-brain disease (MEB [MIM 253280]), a form of
CMD characterized by severe mental retardation and by
ocular and brain abnormalities (Haltia et al. 1997). The
recent mapping of this condition to chromosome 1p32-
34 again suggests that the reduction in merosin expres-
sion is a secondary phenomenon (Cormand et al. 1999).
We recently described a form of CMD characterized
by proximal muscle weakness, muscle hypertrophy, and
early respiratory failure (Muntoni et al. 1998b). Affected
individuals were demonstrated to have a deficiency of
laminin a2 in muscle, but this was a secondary phe-
nomenon, since linkage to the LAMA2 locus on chro-
mosome 6q22-23 was excluded (Muntoni et al. 1998b).
Genomewide linkage analysis of this family has allowed
us to map the locus responsible for this form of CMD
to chromosome 1q42. A second family with similar clin-
ical and histopathological features has been identified.
The family data are consistent with linkage to the same
locus, thereby providing further evidence that this phe-
notype represents a separate form of muscular
dystrophy.
Patients, Material, and Methods
Case Histories
Family 1.—The clinical details of this consanguineous
family from the United Arab Emirates (fig. 1A) have been
reported elsewhere (Muntoni et al. 1998b) and are sum-
marized in table 1. Early motor milestones were delayed
in the four affected children; they were able to walk but
could not run, and they rose from the floor with the use
of a Gower maneuver. Facial weakness, generalizedmus-
cle hypertrophy, andwasting of the sternocleidomastoids
and pectoralis muscle were consistent features. For 19
years, there was no significant progression of the muscle
weakness; however, the two oldest girls died of respi-
ratory complications, one at age 4 years and the other
at age 7 years. The two remaining children, ages 8 and
5 years, were found to be hypoventilating at night and
have been ventilated, by use of nocturnal ventilation via
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Table 1
Summary of Clinical Features
SEVERITY OF CLINICAL FEATURES OF
PATIENTS INa
FAMILY 1 FAMILY 2
CLINICAL FEATURE II.1 II.2 II.3 II.4 II.1 II.2
Sex F F F M F F
Age:
In 1999 (years) D D 12 9 8 3
At presentation (mo) 20 24 28 0 3 18
At sitting (mo) 8 8 8 10 12 7
At walking (mo) 20 24 28 18 30 18
Muscle weakness:
Facial muscles      
Neck muscles      
Shoulder girdle      
Limb girdle      
Distal muscles      
Muscle hypertrophy      
Contractures:
Spine NA NA    
Achilles tendon      
Elbows      
Respiratory involvement     NA NA
CK elevation      
Muscle biopsy:
Dystrophic changes      NA
Reduction of laminin-a2      NA
a D = deceased;  = mild;  = moderate;  = severe;  = absent; NA =
not available.
a biphasic positive airway pressure (BiPAP) machine,
with excellent results. Intellect was normal. Investiga-
tions revealed grossly elevated creatine kinase (CK) levels
in all the children (range 2,270–7,650 IU/liter; normal
values !190 IU/liter). Muscle needle-biopsy samples
showed a dystrophic picture in all four children (fig. 2a),
with normal immunolabeling for dystrophin and for a,
b, and g sarcoglycans (not shown). Antibodies to lam-
inin a2 showed reduced labeling on several fibers (fig.
2b). Expression of integrins a7 and b1D was also re-
duced on the same fibers (not shown). Laminin a5 was
overexpressed in the youngest girl but not in the biopsy
samples from the other children.
Family 2.—Family 2 is a German nonconsanguineous
family with two affected sisters and a healthy older boy
(fig. 1B and table 1). The older sister, now age 11 years,
presented with generalized hypotonia and delayedmotor
milestones during the 1st year of life. She sat at age 12
mo and walked at age 30 mo. At age 18 mo, she had
an episode of spontaneous rhabdomyolysis. She is cur-
rently able to walk a distance of 200–300 m. At a recent
examination, she showed symmetric weakness that was
more pronounced proximally than distally. She had fa-
cial weakness and hypertrophy of the gastrocnemius and
quadriceps. She could rise from the floor, by use of a
Gower maneuver, in 5 s. Her younger sister, age 5 years,
was similarly affected. She sat unsupported at age 7 mo
and walked at age 18 mo. At age 15 mo she had a
rhabdomyolysis develop during an intercurrent infec-
tion. On examination at age 5 years, she had generalized
muscle weakness and rose from the floor by use of a
Gower maneuver. She had mild bilateral hypertrophy of
the gastrocnemius and quadriceps, and there was a mild
facial weakness. Cognitive development was normal.
Findings from cardiological examination and from ech-
ocardiography were normal in the younger sister; in the
older sister, the left-ventricular fractional shorteningwas
in the lower range of normal. Serum CK levels were
grossly elevated in both children (range 1,729–4,000
IU/liter).
The muscle-biopsy sample showed a dystrophic pic-
ture with normal expression of dystrophin and of pro-
teins of the sarcoglycan complex. Immunostaining for
the laminin-a2 chain of merosin showed marked vari-
ation of expression from fiber to fiber (not shown). Lam-
inins a5 and a4 were overexpressed.
Genotypic Analysis
After informed consent was obtained, DNA extraction
from whole-blood samples was performed by use of pro-
teinase K/SDS digestion, followed by phenol/chloroform
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Figure 2 Frozen sections of the muscle-biopsy samples from patients II.4 (a–c, e, and f) and II.3 (d) from family 1; sections were stained
with hematoxylin and eosin (a) and were immunolabeled for laminin-a2 (b), heparan sulfate proteoglycan (c), nidogen (d), a-actinin 2 (e), and
actin (f). Note the dystrophic morphology; the reduced laminin-a2 on some fibers but normal expression of heparan sulfate proteoglycan; and
the presence of nidogen, a-actinin 2, and actin. Bars = 50 mm (bar in a also applies to panels b–d, and e).
extraction, according to standard procedures. Each
member of family 1 was typed with the use of the ABI
linkage mapping set I. This consisted of 358 fluorescent,
highly informative (CA)n-repeat microsatellite markers
located at average intervals of 10 cM.
The PCR reactions were performed with the use of
12.5 ng genomic DNA, 1 # GeneAmp PCR buffer II,
250 mM each dNTP, 2.5 mM MgCl2, 1.25 pmol of both
forward and reverse primers, and 0.25 UAmpliTaqGold
DNA polymerase (PE Biosystems) in a final volume of
5 ml. PCR amplification was done by means of a 9600
thermal cycler (PE Biosystems), with use of the param-
eters recommended by the manufacturer.
Amplified products were separated by electrophoresis,
with use of a denaturing 5% polyacrylamide gel (Gene
Page Plus; Amresco), on an ABI PRISM 377 DNA se-
quencer (PE Biosystems). Markers were typed by use of
GENESCAN, version 2.02, and GENOTYPER, version
2.01, software (PE Biosystems). For the refinement of
the candidate area on chromosome 1q42, markers
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Figure 3 Ideogram of chromosome 1 and markers within the
CMD1B critical region. The unbroken-and-dashed line represents the
minimal and maximal critical regions. These regions are defined by
the recombination events in family 1 (in patient II.2, between D1S459
and D1S2800; in patient II.4, between D1S2860 and D1S2871). Dis-
tances between adjacent markers are in centimorgans, on the basis of
the data from the Ge´ne´thon database. The map positions of four func-
tional candidate genes, on the basis of the GeneMap’98 (International
Radiation Hybrid Mapping Consortium) GB4 map, are indicated as
follows: LBR, ACTA1, NID, and ACTN2.
D1S2860, D1S2894, D1S2871, D1S2833, D1S2709,
and D1S459, selected from the Ge´ne´thon collection (Dib
et al. 1996), were studied in addition to markersD1S213
and D1S2800 from the ABI panel. Primers were pur-
chased from PE Biosystems. In all cases, the forward
primer was modified, at the 5′ end, with a FAM, TET,
or HEX fluorescent label. The order and distance be-
tween markers used in the linkage analysis are depicted
in figure 3.
Linkage Analysis
Linkage analysis was performed with the use of the
LINKAGE 5.2 package, according to the assumptions
of autosomal recessive inheritance, an equal recombi-
nation frequency for males and females, and a disease-
gene frequency of .0001. Two-point LOD scores were
calculated by use of the MLINK program. Allele fre-
quencies were calculated either with reference to the Ge´-
ne´thon database, where possible, or on the basis of our
own data from a total of 92 individuals from 18 con-
sanguineous families primarily of Turkish and Asian
origin.
Muscle Biopsy and Immunohistochemistry
Muscle needle-biopsy samples were available from all
affected children in family 1 and from the oldest sister
in family 2. All samples were frozen and were stained
with a panel of histological and histochemical stains,
according to standard procedures (Dubowitz 1985). Un-
fixed cryostat sections were immunolabeled with anti-
bodies against the following candidate proteins: nidogen
(rabbit polyclonal; kindly provided by Dr. R. Timpl),
skeletal-muscle a-actin (mouse monoclonal; Dako), a-
actinin 2 (rabbit polyclonal; kindly provided by Dr. A.
Beggs), and heparan sulfate proteoglycan (perlecan)(rat
monoclonal; Chemicon). This was followed by use of
an appropriate biotinylated secondary antibody and
Texas red conjugated to streptavidin, as described else-
where (Sewry et al. 1995).
Results
Exclusion of the Known CMD Loci
Linkage to the following loci responsible for CMD
was excluded: LAMA2 (Hillaire et al. 1994; Helbling-
Leclerc et al. 1995a, 1995b; Naom et al. 1997), RSMD1
(MIM 602771) (Moghadaszadeh et al. 1998), MEB
(Cormand et al. 1999), FCMD (Toda et al. 1993), and
the locus for integrin a7 with markers (Hayashi et al.
1998).
Assignment of the Novel Locus in Family 1
The genomewide search identified five markers for
which all four affected children were homozygous.
These markers were located on chromosomes 1p, 1q,
11q, 18p, and 19q. We subsequently selected addi-
tional markers located immediately adjacent to and
closely flanking each of these five markers, by use of
the Ge´ne´thon database. These markers allowed us to
exclude all but one of these regions, since the neigh-
boring markers did not identify a stretch of homo-
zygosity (at least one affected individual was hetero-
zygous ) . F ine mapping around D1S213 on
chromosome 1q confirmed this marker to be part of
an original area of homozygosity by descent, an area
that included markers D1S2871, D1S213, D1S2833,
D1S2709, and D1S459.
Patient II.2 in family 1 had a recombination of the
maternal chromosome, between D1S2860 and
D1S2871. Her younger brother (patient II.4) had a
recombination of the paternal chromosome, between
markers D1S459 and D1S2800. These two recombi-
nation events define the critical region as being 6 !
15 cM, depending on the exact site of recombination.
Since the clinical and histopathological features of
family 2 were identical to those of family 1, we tested
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Table 2
Two-Point LOD Scores for Linkage between the CMD1B Locus and
Chromosome 1q42 Markers
LOD SCORE AT v =
LOCUS AND
FAMILY .00 .01 .05 .10 .20 .30 .40
D1S2860:
1 3.70 .26 .78 .87 .74 .48 .20
2 .72 .71 .62 .50 .30 .14 .03
Total 2.98 .97 1.40 1.37 1.04 .62 .23
D1S2894:
1 .24 .23 .19 .15 .08 .03 .01
2 .43 .40 .32 .23 .08 .02 .01
Total .67 .63 .51 .38 .16 .05 .02
D1S2871:
1 2.29 2.24 2.04 1.79 1.28 .74 .23
2 .72 .70 .61 .50 .30 .13 .03
Total 3.01 2.94 2.65 2.29 1.58 .87 .26
D1S213:
1 2.85 2.80 2.59 2.32 1.75 1.16 .56
2 .72 .70 .61 .50 .30 .13 .03
Total 3.57 3.50 3.20 2.82 2.05 1.29 .59
D1S2833:
1 1.52 1.49 1.36 1.19 .86 .54 .23
2 .42 .41 .37 .31 .20 .10 .02
Total 1.94 1.90 1.73 1.50 1.06 .64 .25
D1S2709:
1 1.43 1.31 1.19 1.05 .75 .46 .19
2 .43 .42 .37 .32 .20 .10 .02
Total 1.86 1.73 1.56 1.37 .95 .56 .21
D1S459:
1 1.38 1.35 1.23 1.08 .78 .48 .19
2 .42 .41 .37 .31 .20 .10 .02
Total 1.80 1.76 1.60 1.39 .98 .58 .21
D1S2800:
1 3.20 .74 1.25 1.31 1.10 .76 .37
2 .73 .70 .61 .51 .31 .14 .03
Total 2.47 1.44 1.86 1.82 1.41 .90 .40
the hypothesis that this family was also linked to the
chromosome 1q42 locus. As can be seen in figure 1B,
the two affected sibs shared the same genotype for the
chromosome 1q markers, whereas the healthy sib in-
herited only one of the two at-risk haplotypes.
Two markers gave significant positive cumulative
LOD scores (13), with the highest score being 3.57
( ), for D1S213 (table 2). Similar LOD scores werev = .00
obtained by use of allele frequencies calculated on the
basis of CEPH families and our own data.
We also studied 17 additional consanguineous families
with CMD, for linkage to this locus. We found no ev-
idence of linkage to this locus in any of these families
(data not shown). This was not surprising, since none
of these 17 families had either clinical features similar
to those of our two linked families or a reduction of the
laminin-a2 chain of merosin in the muscle-biopsy sam-
ples.
Muscle Biopsy: Exclusion of Possible Candidate
Proteins
As previously reported, the biopsy samples showed
dystrophic changes and a reduction of laminin a2 on
some fibers in the affected members in family 1 (fig. 2b)
and in the propositus in family 2 (not shown). Expres-
sion of integrins a7 and b1D was also reduced on the
same fibers (data not shown), whereas heparan sulfate
proteoglycan was normal on all fibers (fig. 2c), including
those fibers with reduced laminin a2 and integrins.
Several proteins expressed in skeletal muscle have been
mapped to the interval D1S2860–D1S2800. This region
includes the genes for nidogen (NID), skeletal-muscle a-
actin (ACTA1), a-actinin 2 (ACTN2), and the lamin B
receptor (LBR). We observed normal immunocytochem-
ical expression of nidogen, a-actin, and a-actinin 2 in
the skeletal muscle–biopsy samples from two affected
individuals in family 1 (figs. 2d–f) and from the pro-
positus in family 2.
Discussion
The two families reported in the present study have
similar clinical and histopathological features, which
suggests that they are affected by the same disease. Some
features of their presentation and clinical symptoms are
shared between CMD and LGMD. The muscle hyper-
trophy, in particular, is common to several forms of
LGMD; however, the selective muscle weakness affecting
the neck muscles, the sternomastoids, the facial muscles,
and the diaphragm is unusual in the early stages of
LGMD. These children all presented in infancy, and
long-term follow-up showed that the muscle weakness
is static, with the exception of the progressive respiratory
failure, as is observed in several forms of CMD. Intellect
is normal, and there is no evidence of either CNS or
peripheral-nervous-system involvement. Levels of serum
CK are grossly elevated, and the muscle-biopsy samples
show similar dystrophic changes in all cases, with re-
duced expression of the laminin-a2 chain of merosin.
The normal expression of perlecan indicates that there
is no generalized abnormality of the basal lamina. How-
ever the reduced expression of the integrins associated
with the laminin-a2 chain suggests that the primary de-
fect may be in the interaction between the basal lamina
and the sarcolemma.
The various known loci responsible for CMD have
been excluded by linkage analysis, indicating that the
merosin deficiency is a secondary phenomenon. The nor-
mal expression of proteins of the sarcoglycan complex
excludes the corresponding forms of LGMD (Campbell
et al. 1995). Whole-genome linkage data and recombi-
nant analysis allowed us to exclude 195% of the genome
and to establish the locus for this form of CMD, on
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chromosome 1q42 (fig. 3). In these families, we were
able to refine the mapping to 1q to an interval of 6–15
cM. Fine mapping of the recombination breakpoints will
allow us to further define this interval (fig. 3). Families
1 and 2 potentially share a haplotype at markers
D1S2709 and D1S459, suggesting that the CMD1B dis-
ease locus could be very close to them (the markers are
!1 cM apart; fig. 3). Allele 2 at D1S2709 is the most-
common allele at this locus (frequency .32), and allele
1 at D1S459 is the second-most-common allele (fre-
quency .23). The frequency of these two alleles occurring
together in the population studied, on the basis of 48
chromosomes, is .125. Taken together with the different
ethnic origins of the two families, these data reduce the
likelihood of a disease-associated haplotype at these two
markers, although it cannot be discounted.
Four functional candidates have been mapped to this
region: nidogen, an extracellular-matrix protein; a-ac-
tinin 2; a-actin; and lamin B receptor. For three of these
proteins (nidogen, a-actinin 2, and a-actin), we have
been able to rule out a “complete knockout.” In light
of the reduced expression of the laminin-a2 chain and
the integrins, the normal immunocytochemistry for ni-
dogen makes it an unlikely candidate. Mutations in the
a-actin gene have been reported in children who have a
form of congenital myopathy with actin accumulation
but with no reduction in extracellular-matrix proteins
(Goebel et al. 1997; Nowak et al. 1999). It is unlikely
that the gene for a-actinin 2 is responsible for this form
of CMD, since we observed normal immunocytochem-
ical expression and since we are not aware of any direct
links between this protein and the extracellular matrix.
We have not been able to study the lamin B receptor
with the use of a suitable antibody; however, other stud-
ies have shown that this protein is predominantly ex-
pressed in interstitial cells in skeletal and cardiac muscle
(Manilal et al. 1999).
In summary, we have mapped a locus for a clinically
and pathologically distinct form of CMD to chro-
mosome 1q42. We suggest calling this disorder
“CMD1B” (CMD1A representing CMD with primary
merosin deficiency). These patients have early-onset
weakness, generalized muscle hypertrophy, selective
muscle weakness, ankle contractures, and a rigid
spine. Follow-up data show that there is little func-
tional skeletal-muscle deterioration over many years.
These patients have a secondary, partial deficiency of
the laminin-a2 chain, suggesting that the primary de-
fect may be in the assembly of the basal lamina.
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